Results
SECONDARY, RHINOSINUSITIS
A total of 106 patients were randomized to receive prednisolone as systemic steroid (n=53, steroid=S) or a placebo (n=53, P). 80 patients completed the medication regimen. This included 41 patients in the steroid and 39 patients in the placebo group (intention-to-treat group). 61 patients completed the 24 months follow-up (per protocol group) (CONSORT diagram of the study.Patient demographics of the intention-to-treat group (n=80) showing no significant differences between the steroid and the placebo group.Baseline testing for all primary and secondary outcome measures as well as for the Lund-Mackay score (intention-to-treat group, n=80).There were no significant differences between the steroid and the placebo group, SNQOL, sinonasal quality of life; GQOL, general quality of life; RSDI, rhinosinusitis.Table comparing the baseline demographics and baseline characteristics for the intention-to-treat (n=80) and the dropout (n=26) groups (A) demographics for the steroid group (B) demographics for the placebo group (C) further characteristics for the steroid group (D) further characteristics for the placebo group.